Search This Blog

Wednesday, June 9, 2021

Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021

 Idorsia Ltd (SIX: IDIA) today announced that nine abstracts for

daridorexant, the company's investigational dual orexin receptor 
antagonist for the treatment of adults with insomnia, will be presented 
at SLEEP 2021. The annual joint meeting of the American Academy of Sleep 
Medicine and the Sleep Research Society is conducted virtually from June 
10-13. 
 
   Antonio Olivieri, Senior Vice President, Head of Global Medical Affairs 
of Idorsia commented: 
 
   "As a company with a strong scientific core rooted in innovative small 
molecules, Idorsia aims to transform the horizon of therapeutic options. 
We look forward to presenting new data from our Phase 3 clinical program 
and other important new data on daridorexant. This reflects our 
commitment to advance research for insomnia, a condition that can 
substantially impact the physical and mental health of patients and 
remains an area with great unmet need." 
https://www.marketscreener.com/quote/stock/IDORSIA-LTD-35837944/news/Press-Release-nbsp-Idorsia-to-present-new-Phase-3-data-on-daridorexant-in-insomnia-at-SLEEP-2021-35553251/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.